| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 28, 2006
Accepted on January 17, 2007
Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio; Novartis Institutes for Biomedical Research, Cambridge, MA; PharmaWrite, LLC, Princeton, NJ; Novartis Pharmaceuticals Corp. East Hanover, NJ; Panum Institute, University of Copenhagen, Copenhagen, Denmark; Institute of Biomedical Engineering, National Research Council, Padova, Italy
* To whom correspondence should be addressed. E-mail: balas{at}uthscsa.edu.
Aims/hypothesis: Vildagliptin is a selective DPP-4 inhibitor that augments meal-stimulated levels of biologically active GLP-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces HbA1c in type 2 diabetes (T2DM). However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration.
Methods: 16 T2DM (age=48±3y; BMI=34.4±1.7 kg/m2; HbA1c=9.0±0.3%) participated in a randomized, double-blind, placebo-controlled trial. On separate days patients received 100 mg vildagliptin or placebo at 5:30PM followed 30 min later by a meal tolerance test (MTT) performed with double tracer technique (3-3H-glucose intravenously and 1-14C-glucose orally).
Results: Following vildagliptin, suppression of endogenous glucose production (EGP) during 6 hours MTT was greater than with placebo (1.02±0.06 vs 0.74±0.06 mg/kg•min, p=0.004), and insulin secretion rate (ISR) increased by 21% (p=0.003 vs PBO) despite significant reduction in mean plasma glucose (213±4 vs 230±4 mg/dl, p=0.006). Consequently, ISR[AUC] ÷ plasma glucose[AUC] increased by 29% (p=0.01). Suppression of plasma glucagon during MTT was 5-fold greater with vildagliptin (p<0.02). The decline in EGP was positively correlated (r=0.55, p<0.03) with the decrease in fasting plasma glucose (
= -14 mg/dl).
Conclusions: During MTT, vildagliptin augments insulin secretion and inhibits glucagon release, leading to enhanced suppression of EGP. During the postprandial period, a single dose of vildagliptin reduced plasma glucose levels by enhancing suppression of EGP.
This article has been cited by other articles:
 |
|
 |
|
  K. Azuma, Z. Radikova, J. Mancino, F. G. S. Toledo, E. Thomas, C. Kangani, C. Dalla Man, C. Cobelli, J. J. Holst, C. F. Deacon, et al. Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 459 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mari, W. A. Scherbaum, P. M. Nilsson, G. Lalanne, A. Schweizer, B. E. Dunning, S. Jauffret, and J. E. Foley Characterization of the Influence of Vildagliptin on Model-Assessed -Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rosenstock, J. E. Foley, M. Rendell, M. Landin-Olsson, J. J. Holst, C. F. Deacon, E. Rochotte, and M. A. Baron Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance Diabetes Care, January 1, 2008; 31(1): 30 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ahren Dipeptidyl Peptidase-4 Inhibitors: Clinical data and clinical implications Diabetes Care, June 1, 2007; 30(6): 1344 - 1350. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
